Using Comprehensive Genomic Profiling to Identify Rare Subsets of Merkel Cell Carcinoma
Ryan C. DeCoste, MD, discusses how comprehensive genomic profiling can be used to identify rare subsets of patients with Merkel cell carcinoma.
Ryan C. DeCoste, MD, QEII Health Sciences Centre, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada, discusses how comprehensive genomic profiling can be used to identify rare subsets of patients with Merkel cell carcinoma.
Merkel cell carcinoma is a relatively rare but highly aggressive skin cancer, according to DeCoste. A previous publication identified a subset of these patients, making up approximately 80% of cases, are associated with a viral oncogenic pathogenesis, which incorporates Merkel cell papilloma virus DNA into precursor cells for subsequent tumorigenesis. However, subsequent to this, a smaller subset was thought not to be associated with this virus and more likely due to UV-induced DNA damage.
Based on these observations, Merkel cell carcinoma can be classified in 1 of 2 categories: virus-positive or virus-negative, and these subsets each have distinct mutational profiles, DeCoste notes.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
